Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage

Authors:

Abstract
A light-activated prodrug delivers both a DNA damaging metal center and a cytochrome P450 inhibitor to prevent drug resistance.
Funding Information
  • Fundación Séneca (19020/FPI/13)
  • National Institute of General Medical Sciences (5R01GM107586)
  • American Cancer Society (RSG-13-079-01-CDD)
  • Ministerio de Economía y Competitividad

This publication has 60 references indexed in Scilit: